SIRONAX

about us

Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research.

company news

Aug 02, 2022

Sironax Announces Closing of $200 Million Series B Financing

2017-09

Sironax (Cayman) founded
2018-06

Seed financing
2019-04

First RIPK1i preclinical candidate SIR0365 nominated
2019-09

Series A financing
2019-11

First healthy subject dosed for SIR0365
2020-08

Healthy subject Ph1a completed for SIR0365
2020-12

First Ph1b patient study initiated SIR0365
2021-08

Second Ph1b study initiated for SIR0365
2021-09

Biologics programs jump-started
2021-12
- First healthy subject dosed for SIR2446
- SIR0365 first Ph1b patient study topline data readout
2022-08

Series B financing

2022-08

Series B financing
2021-12
- First healthy subject dosed for SIR2446
- SIR0365 first Ph1b patient study topline data readout
2021-09

Biologics programs jump-started
2021-08

Second Ph1b study initiated for SIR0365
2020-12

First Ph1b patient study initiated SIR0365
2020-08

Healthy subject Ph1a completed for SIR0365
2019-11

First healthy subject dosed for SIR0365
2019-09

Series A financing
2019-04

First RIPK1i preclinical candidate SIR0365 nominated
2018-06

Seed financing
2017-09

Sironax (Cayman) founded

Pipeline

RESEARCH AREAS

CAREERS

ABOUT US

INNOVATION

MEDIA

CAREERS